Everest Medicines Limited (stock code: 01952) disclosed its latest monthly return, covering movements in securities for January 2026. The company’s authorized share capital stood at 500,000,000 ordinary shares at a par value of USD 0.0001, totaling USD 50,000. No changes were recorded in the authorized or issued capital during the reporting period, and the issued share count remained 353,577,866 shares.

The public float requirement remained compliant at the prescribed minimum of 25%. Meanwhile, the outstanding share options under the Pre-IPO Employee Share Option Plan reached 158,573 shares, and the Post-IPO share option scheme had 21,615,034 outstanding after a lapse of 196,219 options. Additionally, 3,013,474 ordinary shares could be issued pursuant to Pre-IPO restricted stock units, while 1,631,713 shares could be issued under the Post-IPO share award scheme. During the month, 52,414 restricted stock units vested under the Pre-IPO plan, while 80,235 and 60,126 units were canceled under the Pre-IPO and Post-IPO plans respectively.

No new shares were issued, and no treasury shares were utilized, leaving total issued shares and treasury shares unchanged.